Name: Cell 2025
Start: 2025-11-11 00:00:00
End: 2025-11-12 00:00:00
Location: Cell 2025

Company News » Events » Cell UK 2025

We’re excited to announce our participation in Cell 2025, taking place 11–12 November 2025 at the Novotel London West, UK. Hosted by Oxford Global as part of their NextGen Biomed series, this premier event brings together the brightest minds and leading organizations driving the future of cell culture, bioprocessing, and advanced therapy development.

Over two dynamic days, Cell 2025 will unite more than 500 industry leaders, scientists, and innovators from across the cell and gene therapy ecosystem. Expect a packed agenda featuring:

Expert presentations and panels on cell & gene therapy manufacturing, automation, and next-generation process design
Interactive networking sessions and pre-arranged 1-2-1 meetings connecting you directly with potential partners, clients, and collaborators
A vibrant Start-Up Zone, spotlighting emerging biotech ventures and breakthrough technologies
The prestigious Cell Leaders Awards 2025, celebrating excellence across the cell and advanced therapy sectors

As the field continues to evolve, Cell 2025 offers a unique platform to explore how innovations in AI, automation, and scalable bioprocessing are transforming therapeutic development and manufacturing.

We’ll be there to connect, collaborate, and share insights on the latest solutions shaping the next generation of biomedical innovation.

Join us at Booth #38, to discover, network, and drive the future of cell and gene therapy together!

Highlights

Shimobi Onuoha, PhD,
Chimeris

Dr. Onuoha’s talk at Cell UK: Engineering Potent In-Vivo Immune Cell Therapeutics

Date and time: November 11^th, 2025, 10:15-10:40

Dr. Onuoha holds a PhD in Chemistry from the University of Cambridge and has extensive experience in the biotech space, particularly in antibody and CAR T-cell research. He’s published over 30 papers in the area of biologics and CAR T-cell development and has worked at several leading companies in the field.

Abstract:

Despite remarkable success in haematological malignancies, conventional CAR T-cell therapies face major limitations: complex ex vivo manufacturing, variable product quality, delayed availability, and potentially significant toxicity from prolonged immune activation. These constraints restrict their broader use, particularly in autoimmune diseases. We describe a next-generation in vivo CAR T platform that delivers potent CAR constructs directly to T cells in-vivo without the need for lymphodepletion or cell processing, allowing precise control over activity and safety